Stock 1061 ESSEX BIO-TECHNOLOGY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Essex Bio-Technology Limited

Equities

1061

KYG312371035

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-04-29 am EDT 		5-day change 1st Jan Change
2.24 HKD +2.28% Intraday chart for Essex Bio-Technology Limited -3.45% -10.04%
Mar. 19 Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover MT
Mar. 18 Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,610 3,641 2,463 2,848 2,401 1,413
Enterprise Value (EV) 1 2,488 3,526 2,426 2,742 2,347 1,192
P/E ratio 11.4 x 12.3 x 11.5 x 8.52 x 11 x 5.31 x
Yield 1.4% 1.35% 1.17% 1.92% 1.55% 3.61%
Capitalization / Revenue 2.22 x 2.85 x 2.52 x 1.74 x 1.82 x 0.83 x
EV / Revenue 2.12 x 2.76 x 2.48 x 1.67 x 1.78 x 0.7 x
EV / EBITDA 8.44 x 9.33 x 8.85 x 6.54 x 6.98 x 2.96 x
EV / FCF 31.8 x 274 x -13.4 x 430 x 35.6 x 5.83 x
FCF Yield 3.14% 0.37% -7.48% 0.23% 2.81% 17.2%
Price to Book 2.81 x 3.04 x 1.73 x 1.64 x 1.39 x 0.73 x
Nbr of stocks (in thousands) 578,750 577,937 576,881 575,436 571,603 567,575
Reference price 2 4.510 6.300 4.270 4.950 4.200 2.490
Announcement Date 3/18/19 3/30/20 3/25/21 3/25/22 3/29/23 3/26/24
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,176 1,279 978.1 1,638 1,318 1,707
EBITDA 1 294.8 378.1 274 419 336.2 402.7
EBIT 1 275.7 355.1 251.6 393.8 302 351.6
Operating Margin 23.43% 27.76% 25.72% 24.05% 22.92% 20.6%
Earnings before Tax (EBT) 1 273.1 351.8 250.9 394.5 260.3 346
Net income 1 231.1 302.5 218.9 346 225.4 275.3
Net margin 19.64% 23.64% 22.38% 21.13% 17.11% 16.13%
EPS 2 0.3944 0.5113 0.3728 0.5813 0.3828 0.4690
Free Cash Flow 1 78.18 12.89 -181.5 6.383 65.84 204.7
FCF margin 6.64% 1.01% -18.55% 0.39% 5% 11.99%
FCF Conversion (EBITDA) 26.52% 3.41% - 1.52% 19.58% 50.83%
FCF Conversion (Net income) 33.83% 4.26% - 1.84% 29.21% 74.36%
Dividend per Share 2 0.0630 0.0850 0.0500 0.0950 0.0650 0.0900
Announcement Date 3/18/19 3/30/20 3/25/21 3/25/22 3/29/23 3/26/24
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 122 115 37 106 53.8 221
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 78.2 12.9 -181 6.38 65.8 205
ROE (net income / shareholders' equity) 27.7% 28.5% 16.7% 21.9% 13% 15.1%
ROA (Net income/ Total Assets) 13.2% 12.6% 6.99% 9.31% 6.77% 7.93%
Assets 1 1,750 2,404 3,132 3,714 3,330 3,470
Book Value Per Share 2 1.610 2.070 2.470 3.010 3.030 3.390
Cash Flow per Share 2 0.5400 0.8200 1.040 1.170 0.9500 0.9000
Capex 1 21.3 39.4 97.1 90 89.5 21
Capex / Sales 1.81% 3.08% 9.93% 5.5% 6.79% 1.23%
Announcement Date 3/18/19 3/30/20 3/25/21 3/25/22 3/29/23 3/26/24
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ESSEX BIO-TECHNOLOGY LIMITED Stock Essex Bio-Technology Limited
-10.04% 159M
CSL LIMITED Stock CSL Limited
-4.06% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.97% 39.82B
UCB Stock UCB
+56.59% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.82% 15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-8.82% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-16.29% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-41.58% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.14% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-7.02% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1061 Stock
  4. Financials Essex Bio-Technology Limited